<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04653428</url>
  </required_header>
  <id_info>
    <org_study_id>D-TRIK</org_study_id>
    <nct_id>NCT04653428</nct_id>
  </id_info>
  <brief_title>German Registry for Transcatheter Tricuspid Valve Interventions</brief_title>
  <official_title>German Registry for Transcatheter Tricuspid Valve Interventions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LMU Klinikum</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heart and Diabetes Center North Rhine-Westphalia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heart Center Leipzig - University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mainz University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitätsklinikum Köln</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Essen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>LMU Klinikum</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicentre observational study of patients with severe tricuspid regurgitation and&#xD;
      interventional treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Severe tricuspid regurgitation occurs in around 1.5 % of men and 5.6 % of women and it is&#xD;
      associated with significant morbidity and mortality. Current guidelines recommend cardiac&#xD;
      surgery, especially in those patients who are undergoing left side valve surgery.&#xD;
      Nevertheless many patients are not eligible for surgical tricuspid valve repair due to an&#xD;
      high risk of mortality. Therefore interventional devices for treatment of tricuspid&#xD;
      regurgitation have been established to offer these patients an alternative treatment option.&#xD;
      The aim of this study is to analyse the success and saftey aspects of different&#xD;
      interventional repair techniques for severe tricuspid regurgitation. Therefore in this&#xD;
      prospectively designed observational study clinical, echocardiographic and laboratory&#xD;
      parameters will be collected.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2030</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>All-cause death and heart failure hospitalisation</measure>
    <time_frame>1 year</time_frame>
    <description>All-cause death and heart failure hospitalisation 1 year after transcatheter tricuspid valve treatment (TTVT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause death and heart failure hospitalisation (long-term)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Long-term all-cause death and heart failure hospitalisation after transcatheter tricuspid valve treatment (TTVT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death and heart failure hospitalisation (short-term)</measure>
    <time_frame>30-90 days</time_frame>
    <description>Short-term all-cause death and heart failure hospitalisation after transcatheter tricuspid valve treatment (TTVT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of tricuspid regurgitation after transcatheter tricuspid valve treatment (TTVT)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Assessed by echocardiography, tricuspid regurgitation graded on a 4-grade scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of cardiopulmonal symptoms after transcatheter tricuspid valve treatment (TTVT)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Assessment for cardiopulmonal symptoms include edema scaling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of NYHA classification after transcatheter tricuspid valve treatment (TTVT)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>NYHA classification I, II, III or IV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of 6-minute walking distance test after transcatheter tricuspid valve treatment (TTVT)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Assessed by standardized protocol testing 6-minute walking distance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of quality of life after transcatheter tricuspid valve treatment (TTVT)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Quality of life is assessed by standardized questionnaires including the Minnesota Living with Heart Failure Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of NT-proBNP after transcatheter tricuspid valve treatment (TTVT)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>N-terminal pro Brain Natriuretic Peptide (NT-proBNP) in pg/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural success after transcatheter tricuspid valve treatment (TTVT)</measure>
    <time_frame>At the day of discharge after transcatheter tricuspid valve treatment (TTVT)</time_frame>
    <description>Procedural success is defined as a reduction of the tricuspid regurgitation to at least grade 2+ achieved by interventional treatment</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety outcome after transcatheter tricuspid valve treatment (TTVT)</measure>
    <time_frame>At the day of discharge after transcatheter tricuspid valve treatment (TTVT)</time_frame>
    <description>The saftety outcome contains all complications which occur between the interventional treatment of the tricuspid regurgitation and discharge from the hospital. Data collection includes: mortality with differentiation of cardiac death and non-cardiac death, unplanned cardiac surgery, re-intervention of tricuspid valve, pericardial tamponade, intervention of coronary arteries. Moreover major adverse events as defined by MVARC2 criteria are recorded at discharge from hospital: death with differentiation of cardiac death and non-cardiac death, peri-procedural or spontaneous myocardial infarction, stroke, transient ischemic attack, life-threatening, major or minor bleeding, acute kidney failure, complications of the vascular access.</description>
  </other_outcome>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Tricuspid Regurgitation</condition>
  <condition>Tricuspid Valve Insufficiency</condition>
  <condition>Heart Valve</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Interventional treatment of tricuspid regurgitation</intervention_name>
    <description>Interventional treatment for tricuspid regurgitatin with CE-certified products, e.g. edge-to-edge repair</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with severe symptomatic tricuspid regurgitation, who are not eligible for cardiac&#xD;
        surgery due to a high risk of mortality.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Interventional treatment of severe tricuspid regurgitation (isolated or in combination&#xD;
             with another interventional treatment) with a CE certified product for tricuspid valve&#xD;
             repair&#xD;
&#xD;
          -  Informed consent corresponding to criteria of Good Clinical Practice and the&#xD;
             decleration of Helsinki as well as to standards of the local ethic commission.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No agreement to participation&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jörg Hausleiter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum der LMU Muenchen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jörg Hausleiter, MD</last_name>
    <phone>+49 89 4400 72361</phone>
    <email>joerg.hausleiter@med.uni-muenchen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel Braun, MD</last_name>
    <phone>+4915254848306</phone>
    <email>daniel.braun@med.uni-muenchen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinikum der LMU Muenchen</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jörg Hausleiter</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 17, 2020</study_first_submitted>
  <study_first_submitted_qc>November 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2020</study_first_posted>
  <last_update_submitted>November 28, 2020</last_update_submitted>
  <last_update_submitted_qc>November 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>LMU Klinikum</investigator_affiliation>
    <investigator_full_name>Prof. Dr. med. Jörg Hausleiter</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Tricuspid regurgiation</keyword>
  <keyword>Tricuspid valve insufficiency</keyword>
  <keyword>Interventional treatment</keyword>
  <keyword>Heart valve diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

